Clovis Oncology Stock Price and Value Analysis

Should you buy Clovis Oncology stock? (NasdaqGS:CLVS). Let's see how it does in our automated value investing analysis system.

  • This company has stable growth.
  • This company is not making money.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company pays no dividend.

Inside the CLVS Numbers

CLVS Price
(Clovis Oncology stock price per share)
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Biotechnology stocks
[?] Cash Yield -1982.15%
[?] Free Cash Flow Jitter 25%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 31,487,307 shares shorted. With 142,406,924 shares available for purchase and an average trading volume over the past 10 trading days of 9,455,540, it would take at least 3.33 days for all of the short holders to cover their shorts.

Is Clovis Oncology Stock on Sale?

Based on our analysis, we believe that you should not buy Clovis Oncology right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy CLVS Stock?

Does Clovis Oncology have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.